analysts and calls -- ML Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : analysts and calls -- ML

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tom pope who wrote (213)	12/22/2006 2:01:13 PM
From: tuck	Read Replies (1) of 238

Given this note from September, in which ML calls the value in the best case scenario $45 - $50. Given that this scenario includes a DEA schedule 3 or 4. Given that the stock is well over $50 already, with the DEA yet to rule. And given that the FDA continues to recommend Schedule 2, and that probability of the DEA disagreeing with FDA is less than 50% . . . the note you posted on the TELK thread is just amazing. Message 23124548 They continue to recommend buying in front of the DEA decision in mid-February, even though, by their own numbers there is no reward (unless they have made revisions not disclosed in today's note), and huge risk. Nutty! Very tempted to try my short again. Oh, and they whiffed on their ADLR call, I see. Message 22830930 Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next